Abstract: Objective：To explore the clinical characteristics and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL). Methods：The clinical characteristics and prognostic factors of 36 patients with AITL were retrospectively analyzed, all of whom were treated at the Department of Hematology, Zhongshan Hospital, Fudan University between November 2005 and June 2017, and were confirmed by pathology and immunohistochemistry. Log-rank survival analysis and Cox multivariate analysis were used to analyze the prognostic factors affecting the overall survival (OS) of patients. Results：The median age of 36 patients was 62 (36-79) years old, with 61.1% males (n=22), 97.2% Ann Arbor stage Ⅲ/Ⅳ (n=35), and 69.4% with B symptoms (n=25). Three cases (8.3%) were categorized as 0-1, 5 cases (13.9%) as 2, 13 cases (36.1%) as 3, and 15 cases (41.7%) as 4 and 5 for the international prognostic index (IPI). The median survival time was 24.4 months, and the 3-year OS rate was 49.2%. Five cases were treated with chidamide, one of whom had relapse after complete remission (CR), after GemOx combined with chidamide treatment, reached CR again. The other 4 cases had disease progression (PD) during the first-line treatment. They were treated with chidamide as a part of the second-line treatment. Among whom, 1 case had stable disease (SD) and 3 cases died. Univariate survival analysis showed that multiple serous effusion (P=0.05), CRP >40 mg/L (P=0.001), and neutrophil >7×10^9/L (P=0.004) were the adverse prognostic factors affecting OS. Multivariate analysis showed that CRP >40 mg/L (HR=9.185, 95% CI 2.599-32.462, P=0.001), PLT <150×10^9/L (HR=3.851, 95% CI 1.328-11.167, P=0.013), multiple serous effusion (HR= 3.054, 95% CI 1.105-8.438, P=0.031) were independent prognostic factors for OS. Conclusions：The prognosis of AITL is poor. CRP>40 mg/L, PLT<150×10^9/L, and multiple serous effusion might be independent adverse prognostic factors for OS.